ClinicalTrials.gg
RecruitingNCT05138614STAR-CODUpdated Oct 13, 2026

Supporting Treatment Access and Recovery in COD

An interventional study of Medication for Opioid Use Disorder and MISSION Critical Time Intervention in Opioid Use Disorder and Mental Health Disorder, sponsored by University of Massachusetts, Worcester. Recruiting at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by University of Massachusetts, Worcester · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2022; still recruiting 4 years 8 months later.
Updated Oct 13, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,000
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,223 studies in Opioid-Related Disorders with a site in United States — 246 open to participants now, 316 under way, 18 of them phase 3. Opioid-Related Disorders · United States.

Planned enrollment
45th of 1,098
1,000 · median 56
Started
2022
with 82 others
No phase
571 of 1,223
133 open now
Primary completion
2027-08
later than 175 of 315 live
Registered
792nd of 1,223
by date

Among the 1,223 studies in Opioid-Related Disorders with a site in United States, this one is the 45th largest by planned enrollment of the 1,098 interventional ones that give a count, is one of 83 that started in 2022, is one of 571 with no phase, reaches primary completion later than 175 of the 315 other live ones, and was the 792nd registered.

Opioid-Related Disorders

1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.

Browse Opioid-Related Disorders studies →

Open to participants now

246 of the 1,223 studies in Opioid-Related Disorders with a site in United States are open now. Recruiting first, the newest first:

241 more — sign in →

All 246 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 213 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 76 (36%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,223 studies in Opioid-Related Disorders with a site in United States, or all of them as a file.
02

Study summary

This 4-year study will randomize 1,000 people with co-occurring opioid use and mental health disorders (COD) at medication for opioid use disorder (MOUD) clinics to evaluate the effectiveness of MISSION, a multi-component team approach, or its components with MOUD versus MOUD alone, as well as the incremental benefits of MISSION or its components for improving outcomes. We expect that individuals receiving MISSION or its parts + MOUD will show greater improvement over MOUD alone on: engagement, substance use, and mental health.

Read the detailed description

This is a 5-arm randomized control trial with a fractional factorial design among 1,000 patients across Massachusetts. Patients will be randomized to: 1) MOUD alone; 2) full MISSION (CTI \& DRT \& PS) + MOUD; 3) CTI \& DRT + MOUD; 4) PS \& DRT + MOUD; or 5) CTI \& PS + MOUD (Arms 3-5 are the 3 combinations of 2 MISSION parts). MISSION is a time-limited, cross disciplinary, team-based wraparound approach that provides 6 months of psychosocial treatment combined with assertive outreach, empowering clients to access and engage in care and community services to promote recovery. The MISSION treatment curriculum integrates 3 evidence-based practices along with MOUD: 1) Critical Time Intervention (CTI), a time-limited form of assertive community treatment; 2) Dual Recovery Therapy (DRT), which is integrated mental health and substance use group therapy; and 3) Peer Support (PS), offering support for people in recovery by people in recovery. Participants will receive 6 months of treatment and be followed for 1-year.

Study aims include:

Aim 1: To evaluate the effectiveness of MISSION or its bundled parts with MOUD versus MOUD alone, as well as the incremental benefits of MISSION and its parts + MOUD to improve outcomes 1a-c for CODs.

Hypothesis 1.1: Individuals receiving MISSION or its parts + MOUD will show greater improvement over MOUD alone on: 1a. Engagement (measured by total days in treatment, percentage of days receiving MOUD, and total number of outreach and linkages sessions); 1b. Opioid use and other substance use (measured by self-report days of use and drug screens); and 1c. Mental health (measured by self-report mental health symptoms).

Hypothesis 1.2: MISSION + MOUD will outperform its parts + MOUD but at least one of the three combinations + MOUD will be at least 75% as effective compared to the full MISSION protocol on outcomes 1a-c.

Aim 2: To examine mechanisms of action of MISSION in CODs. Hypothesis 2.1: The effects of MISSION and its bundled parts on health outcomes (mental health, opioid and other substance use) are mediated by treatment participation and other measures (e.g., recovery capital, psychosocial supports, and quality of life). Hypothesis 2.2: The effects of MISSION and its parts on health outcomes are moderated by key patient characteristics (e.g., demographics, severity of COD, and MOUD type).

Aim 3: To conduct a comprehensive economic evaluation of MISSION or its bundled parts and MOUD.

Estimate cost of full MISSION or its bundled parts compared to MOUD alone, and to evaluate cost-effectiveness and return on investment from multiple perspectives, including patient, clinic, healthcare, taxpayer, and societal.

Exploratory Aim: 4. To construct a predictive model that can match optimum combined use of MISSION parts with specific patient's needs for greater improvements in health outcomes, which will inform a future randomized controlled trial on cost-effective patient-level precision intervention assignment.

03

Conditions studied

  • Opioid Use Disorder
  • Mental Health Disorder

Keywords

  • opioid use disorder
  • mental health
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are 18 years-old and older;
  • Are fluent in English or Spanish;
  • Have OUD who (a) are newly admitted into the program with OUD; or (b) who have been active in the program for the treatment of OUD with medications like buprenorphine or naltrexone, but experienced a recent relapse with any substance (e.g., alcohol, cocaine, opioids, or benzodiazepines). This second group is necessary to include because patients who may have been stable for a long period of time may have a relapse and need intensive treatment to help them regain their abstinence and facilitate the path towards recovery. Thus, by taking those newly enrolled and those who were stable on MOUD but had a recent relapse, the second group is clinically similar to the first group and the intervention will be meaningful.;
  • Able to provide consent;
  • Potentially have a concurrent substance use disorder in addition to opioids; and
  • Have a co-occurring mental health disorder (COD) including depression, anxiety, trauma-related disorders, bipolar, and/or schizophrenia, and those who are stable on buprenorphine or naltrexone but have recurrence or worsening at any time of symptoms of any co-occurring mental health disorder (COD) including depression, anxiety, trauma-related disorders, bipolar, and/or schizophrenia, even if the patient has not . Instability is defined in two ways in the study: (a) a substance use relapse; and (b) recurrence to symptom exacerbation in regard to a subject's mental health disorder(s). If subjects do not meet criteria for "a" (i.e., not having a substance use relapse), but they do meet criteria for "b" (i.e., they do in fact have worsening of mental health symptoms), they are then defined as unstable, and will meet study inclusion criteria.

Exclusion criteria

Exclusion Criteria:

  • Are not fluent in English or Spanish;
  • Are acutely psychotic, acutely suicidal with a plan, or homicidal;
  • Are incompetent and unable to provide ; and
  • Have concurrent severe alcohol use disorder or high dose benzodiazepine needing detoxification. This exclusion factor is based on criteria, and those who are currently drinking or with a history of severe alcohol withdrawal (i.e., alcohol related seizures, and delirium tremens) will also be excluded. High dose benzodiazepine is defined as using Lorazepam equivalent of > 10 mg/day; Diazepam > 100 mg/day; Clonazepam 5 mg/ day; Alprazolam 5 mg/day.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Single (Outcomes assessor)
Enrollment
1,000 participants (estimated)

Study arms

  • Experimental
    Full MISSION

    CTI + DRT + PS + MOUD

    Other: Medication for Opioid Use Disorder · Behavioral: MISSION Critical Time Intervention · Behavioral: MISSION Peer Support · Behavioral: MISSION Dual Recovery Therapy

  • Experimental
    CTI & DRT

    CTI + DRT + MOUD

    Other: Medication for Opioid Use Disorder · Behavioral: MISSION Critical Time Intervention · Behavioral: MISSION Dual Recovery Therapy

  • Experimental
    CTI & PS

    CTI + PS + MOUD

    Other: Medication for Opioid Use Disorder · Behavioral: MISSION Critical Time Intervention · Behavioral: MISSION Peer Support

  • Experimental
    DRT & PS

    DRT + PS + MOUD

    Other: Medication for Opioid Use Disorder · Behavioral: MISSION Peer Support · Behavioral: MISSION Dual Recovery Therapy

  • Other
    MOUD only

    MOUD

    Other: Medication for Opioid Use Disorder

Interventions

  • OtherMedication for Opioid Use Disorder

    medication management

    Also known as: MOUD

  • BehavioralMISSION Critical Time Intervention

    offering intensive community-based services that decrease in intensity over time

    Also known as: CTI

  • BehavioralMISSION Peer Support

    including 11 recovery-oriented sessions from someone with lived experience of co-occurring disorders

    Also known as: PS

  • BehavioralMISSION Dual Recovery Therapy

    comprised of 13 structured co-occurring disorders treatment sessions

    Also known as: DRT

06

What researchers measure

Primary outcomes

  1. Engagement in treatment

    Measured by total days in treatment

    Time frame: 6 months

  2. Engagement in medication for opioid use disorder (MOUD)

    Measured by percentage of days receiving MOUD

    Time frame: 6 months

  3. Engagement in outreach and linkage sessions

    Measured by total number of outreach and linkage sessions

    Time frame: 6 months

  4. Self-report opioid use and other substance use

    Measured by self-report days of use

    Time frame: Baseline

  5. Self-report opioid use and other substance use

    Measured by self-report days of use

    Time frame: 3 months

  6. Self-report opioid use and other substance use

    Measured by self-report days of use

    Time frame: 6 months

  7. Self-report opioid use and other substance use

    Measured by self-report days of use

    Time frame: 9 months

  8. Self-report opioid use and other substance use

    Measured by self-report days of use

    Time frame: 12 months

  9. Opioid use and other substance use (drug screen)

    Measured by positive drug screens

    Time frame: 3 months

  10. Opioid use and other substance use (drug screen)

    Measured by positive drug screens

    Time frame: 6 months

  11. Mental health functioning

    Measured by self-report mental health symptoms on Behavior and Symptom Identification Scale (BASIS-24)

    Time frame: Baseline

  12. Mental health functioning

    Measured by self-report mental health symptoms on BASIS-24

    Time frame: 3 months

  13. Mental health functioning

    Measured by self-report mental health symptoms on BASIS-24

    Time frame: 6 months

  14. Mental health functioning

    Measured by self-report mental health symptoms on BASIS-24

    Time frame: 9 months

  15. Mental health functioning

    Measured by self-report mental health symptoms on BASIS-24

    Time frame: 12 months

  16. PTSD symptoms

    Measured by self-report PTSD symptoms on Patient Checklist (PCL-5)

    Time frame: Baseline

  17. PTSD symptoms

    Measured by self-report PTSD symptoms on Patient Checklist (PCL-5)

    Time frame: 3 months

  18. PTSD symptoms

    Measured by self-report PTSD symptoms on Patient Checklist (PCL-5)

    Time frame: 6 months

  19. PTSD symptoms

    Measured by self-report PTSD symptoms on Patient Checklist (PCL-5)

    Time frame: 9 months

  20. PTSD symptoms

    Measured by self-report PTSD symptoms on Patient Checklist (PCL-5)

    Time frame: 12 months

  21. Mental health impairment

    Measured by self-report on World Health Organization Disability Assessment (WHODAS 2.0)

    Time frame: Baseline

  22. Mental health impairment

    Measured by self-report on WHODAS 2.0

    Time frame: 3 months

  23. Mental health impairment

    Measured by self-report on WHODAS 2.0

    Time frame: 6 months

  24. Mental health impairment

    Measured by self-report on WHODAS 2.0

    Time frame: 9 months

  25. Mental health impairment

    Measured by self-report on WHODAS 2.0

    Time frame: 12 months

  26. Psychiatric severity

    Measured by Structured Clinical Interview for DSM-5 (SCID-RV)

    Time frame: Baseline

  27. Health functioning

    Measured by the World Health Organization Quality of Life Scale Brief Version (WHOQOL-BREF)

    Time frame: Baseline

  28. Health functioning

    Measured by the WHOQOL-BREF

    Time frame: 3 months

  29. Health functioning

    Measured by the WHOQOL-BREF

    Time frame: 6 months

  30. Health functioning

    Measured by the WHOQOL-BREF

    Time frame: 9 months

  31. Health functioning

    Measured by the WHOQOL-BREF

    Time frame: 12 months

  32. Motivation for treatment

    Measured by Stages of Change, Readiness, and Treatment Eagerness Scale (SOCRATES)

    Time frame: Baseline

  33. Motivation for treatment

    Measured by SOCRATES

    Time frame: 3 months

  34. Motivation for treatment

    Measured by SOCRATES

    Time frame: 6 months

  35. Motivation for treatment

    Measured by SOCRATES

    Time frame: 9 months

  36. Motivation for treatment

    Measured by SOCRATES

    Time frame: 12 months

  37. Suicide Severity

    Measured by Columbia- Suicide Severity Rating Scale (C-SSRS)

    Time frame: Baseline

  38. Suicide Severity

    Measured by C-SSRS

    Time frame: 3 months

  39. Suicide Severity

    Measured by C-SSRS

    Time frame: 6 months

  40. Suicide Severity

    Measured by C-SSRS

    Time frame: 9 months

  41. Suicide Severity

    Measured by C-SSRS

    Time frame: 12 months

  42. Therapeutic alliance

    Measured by Working Alliance Inventory

    Time frame: Baseline

  43. Therapeutic alliance

    Measured by Working Alliance Inventory

    Time frame: 3 months

  44. Therapeutic alliance

    Measured by Working Alliance Inventory

    Time frame: 6 months

  45. Therapeutic alliance

    Measured by Working Alliance Inventory

    Time frame: 9 months

  46. Therapeutic alliance

    Measured by Working Alliance Inventory

    Time frame: 12 months

  47. Recovery Capital

    Measured by Assessment of Recovery Capital

    Time frame: Baseline

  48. Recovery Capital

    Measured by Assessment of Recovery Capital

    Time frame: 3 months

  49. Recovery Capital

    Measured by Assessment of Recovery Capital

    Time frame: 6 months

  50. Recovery Capital

    Measured by Assessment of Recovery Capital

    Time frame: 9 months

  51. Recovery Capital

    Measured by Assessment of Recovery Capital

    Time frame: 12 months

  52. Chronic pain

    Measured by Chronic Pain assessment

    Time frame: Baseline

  53. Chronic pain

    Measured by Chronic Pain assessment

    Time frame: 3 months

  54. Chronic pain

    Measured by Chronic Pain assessment

    Time frame: 6 months

  55. Chronic pain

    Measured by Chronic Pain assessment

    Time frame: 9 months

  56. Chronic pain

    Measured by Chronic Pain assessment

    Time frame: 12 months

  57. Medication Adherence

    Measured by Medication Adherence Rating Scale

    Time frame: 3 months

  58. Medication Adherence

    Measured by Medication Adherence Rating Scale

    Time frame: 6 months

Secondary outcomes

  1. Mortality

    Data extracted from medical records

    Time frame: 6 months

  2. Quality Adjusted Life Years (QALYs): health

    Measured by self-report on the 5-level EQ-5D (EQ-5D-5L). Scores range from 0 (worst imaginable health) to 100 (best imaginable health).

    Time frame: Baseline

  3. Quality Adjusted Life Years (QALYs): health

    Measured by self-report on the 5-level EQ-5D (EQ-5D-5L). Scores range from 0 (worst imaginable health) to 100 (best imaginable health).

    Time frame: 3 months

  4. Quality Adjusted Life Years (QALYs): health

    Measured by self-report on the 5-level EQ-5D (EQ-5D-5L). Scores range from 0 (worst imaginable health) to 100 (best imaginable health).

    Time frame: 6 months

  5. Quality Adjusted Life Years (QALYs): health

    Measured by self-report on the 5-level EQ-5D (EQ-5D-5L). Scores range from 0 (worst imaginable health) to 100 (best imaginable health).

    Time frame: 9 months

  6. Quality Adjusted Life Years (QALYs): health

    Measured by self-report on the 5-level EQ-5D (EQ-5D-5L). Scores range from 0 (worst imaginable health) to 100 (best imaginable health).

    Time frame: 12 months

  7. Quality Adjusted Life Years (QALYs): quality of life

    Measured by self-report on Patient Reported Outcomes - Preference (PROPr). Scores range from 0 to 100 with higher scores indicating worse quality of life.

    Time frame: Baseline

  8. Quality Adjusted Life Years (QALYs): quality of life

    Measured by self-report on Patient Reported Outcomes - Preference (PROPr). Scores range from 0 to 100 with higher scores indicating worse quality of life.

    Time frame: 3 months

  9. Quality Adjusted Life Years (QALYs): quality of life

    Measured by self-report on Patient Reported Outcomes - Preference (PROPr). Scores range from 0 to 100 with higher scores indicating worse quality of life.

    Time frame: 6 months

  10. Quality Adjusted Life Years (QALYs): quality of life

    Measured by self-report on Patient Reported Outcomes - Preference (PROPr). Scores range from 0 to 100 with higher scores indicating worse quality of life.

    Time frame: 9 months

  11. Quality Adjusted Life Years (QALYs): quality of life

    Measured by self-report on Patient Reported Outcomes - Preference (PROPr). Scores range from 0 to 100 with higher scores indicating worse quality of life.

    Time frame: 12 months

Other outcomes

  1. Economic impact of full MISSION

    Cost of full MISSION and MOUD measured by Patient-Reported Outcomes Measurement Information System-Preference (PROPr)

    Time frame: 6 months

  2. Economic impact of CTI & PS

    Cost of MISSION CTI, PS, and MOUD measured by PROPr

    Time frame: 6 months

  3. Economic impact of CTI & DRT

    Cost of MISSION CTI, DRT, and MOUD measured by PROPr

    Time frame: 6 months

  4. Economic impact of PS & DRT

    Cost of MISSION PS, DRT, and MOUD measured by PROPr

    Time frame: 6 months

  5. Economic impact of MOUD alone

    Cost of MOUD alone measured by PROPr

    Time frame: 6 months

07

Study locations

5 of 5 sites recruiting
  • Behavioral Health Network
    Holyoke, Massachusetts 01040, United States
    Recruiting
    • Herschelle Reaves · Contact
  • Behavioral Health Network
    Orange, Massachusetts 01364, United States
    Recruiting
  • Behavioral Health Network
    Springfield, Massachusetts 01104, United States
    Recruiting
  • UMass Chan Road to Care Clinic
    Worcester, Massachusetts 01601, United States
    Recruiting
  • SaVida Health
    Worcester, Massachusetts 01605, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Consistent with the NIH HEAL Initiative, Underlying Primary Data collected from participants in this project will be made readily available to the public through twice-yearly submissions to the NIMH Data Archive (NDA). In consultation with the University of Massachusetts Medical School's institutional review board (IRB), project consent forms will include relevant information for participants to be made aware that their de-identified data will be available to other investigators as a part of the HEAL Initiative Public Access and Data Sharing Policy.

Supporting information: Study protocol

Time frame: Data will be available upon publication (via an NDA Study) or 1-2 years after the grant end date (August 2026), until 2032 (expiration of NDA Certificate of Confidentiality)

Access criteria: Data will be shared with authorized NDA users.

Data sharing details ↗ · nda.nih.gov

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Aug 2027, 65 months after the start.

Of 465 non-industry interventional studies with no phase under Opioid-Related Disorders, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 47. This study's planned 65 months is above that.

Counting every sponsor, half of 496 studies reached it within 29 months; a quarter within 13 and three quarters within 46.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Aug 2026 → Aug 2027 and completion Aug 2026 → Aug 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2021
First posted
Dec 1, 2021
StartActual
Mar 11, 2022
Primary completionEst.
Aug 31, 2027was Aug 2026
CompletionEst.
Aug 31, 2027was Aug 2026
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 31, 2026→Aug 31, 2027
Oct 13, 2026
Study completion
Aug 31, 2026→Aug 31, 2027
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Primary completion Aug 31, 2026→Aug 31, 2027
    Study completion Aug 31, 2026→Aug 31, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05138614
Collaborators
National Institute of Mental Health (NIMH), University of Massachusetts, Lowell, Cornell University, Harvard Medical School (HMS and HSDM)
Responsible party
David Smelson (Professor, University of Massachusetts, Worcester) — Principal investigator
First posted
Dec 1, 2021
Start date
Mar 11, 2022
Primary completion
Aug 31, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Oct 13, 2026

Study contacts

David Smelson, PsyD
Contact
David.Smelson@umassmed.edu
508-713-5420
Abigail Helm, PhD
Contact
Abigail.Helm@umassmed.edu
413-313-2806
David Smelson, PsyD
principal investigator · University of Massachusetts, Worcester

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion